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Abstract 
Introduction: Clinical presentation and treatment in many disease states vary due to sex- and gender-differences. Sex-related 
pharmacokinetic differences are particularly important for pharmacists. The Accreditation Council for Pharmacy Education (ACPE) 
currently has no standard for the inclusion of gender- and sex-related differences in the didactic PharmD curriculum, but encourages 
advanced pharmacy practice experiences (APPEs) to include diverse populations related to gender. The purpose of this survey is to 
explore faculty incorporation of gender and sex differences within the PharmD didactic curriculum in preparation for a nation-wide 
survey.  Methods: A survey was created to determine how many clinical topics incorporated gender- and sex-related differences and 
to what extent this information was discussed in the classroom. The survey link was emailed to pharmacotherapeutics and 
pharmacokinetics faculty at Midwestern University Chicago College of Pharmacy, University of Illinois at Chicago, Roosevelt 
University, Rosalind Franklin University, and Chicago State University. Chi square analyses were performed to examine relationships 
across participant responses.  Results: A total of 56 faculty members participated in the survey, resulting in a 20% response rate. Of 
these, 30 (54.5%) faculty indicated that they discussed gender- and sex-related differences in the subject area in which they teach. 
Approximately 33% of respondents found gender- and sex-related differences very clinically important. Gender- and sex- related 
differences were taught in a variety of subject areas, including cardiology, diabetes, and chronic obstructive pulmonary disease 
(COPD). Conclusion: With no current standard, faculty members independently choose to include gender- and sex-related differences 
in their lecture topics and the extent of the discussion. Faculty should be aware of this lack of standardization and that they are 
independently responsible for including gender- and sex-related differences in their particular topics.  Because the surveyed faculty 
find gender- and sex-related differences clinically important and literature suggests differences in medications depending on gender 
and sex, further research is planned to provide insight on a national level.  
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Introduction 
The US Department of Health and Human Services (HHS), the 
Health Resources and Services Administration (HRSA) and the 
Office of Women’s Health (OWH) completed a report in 2013 
that reviewed healthcare professional programs, including 
medicine, nursing, dentistry, public health and pharmacy.1    
The report summarized the incorporation of women’s health 
in these different curricula utilizing student surveys and 
curriculum reviews. The report suggests that pharmacy 
students are poorly informed about some women’s health 
issues, including the use of emergency contraceptives. A 
survey of medical students suggested that respondents felt 
there was brief to moderate coverage of women’s health 
topics in the curriculum. Only about half of nursing students 
responded that knew how to meet needs specific to women. 
Twenty-five percent of dental schools do not offer courses 
that are specific to women. The authors recommended that 
improving integration of women’s health education could be 
achieved with service learning in women’s health, women’s 
health clerkships and fellowships, creation of core 
competencies in women’s health and much more.1 Women’s  
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health is an area that should be included in all healthcare 
curricula to ensure the needs of the patient are met.  
 
Men and women in many disease states present differently 
due to sex and gender differences. Sex is a biological 
classification, where there are physiological differences 
between males and females. Gender is associated with 
societal, cultural and environmental differences. It is the 
responsibility of healthcare providers to recognize these 
differences in sex and gender so that the patient may be 
diagnosed, managed and treated appropriately. While 
pharmacists may have an awareness of pharmacokinetic 
differences, there are other concerns that should be 
considered as well. 
     
Cardiovascular disease is the number one cause of mortality in 
both men and women; therefore it is important for all 
healthcare professionals to understand how men and women 
present differently in the disease. Women are more likely to 
present with fatigue, indigestion and back pain compared to 
men who often present with left sided chest pain during a 
myocardial infarction (MI).2 After experiencing a MI, women 
are less likely to be prescribed an angiotensin converting 
enzyme inhibitor (ACE-I) and aspirin therapy compared to 
men.3 When women are prescribed an ACE-I, they are more 
likely to develop a cough from the medication as compared to 
men.4 
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Women have higher lifetime rates of depression compared to 
men, and there are differences in clinical presentation.5 
Women’s symptoms often include stress, sleep problems and 
loss of interest. Men often present with aggression, substance 
abuse, and risk taking behavior. Women tend to respond 
better to selective serotonin reuptake inhibitor (SSRI) therapy 
than men.6 
 
One theory as to why men and women respond differently to 
certain drug therapies may be due to differences in the 
medication pharmacokinetics or individual patient 
pharmacodynamics. Women tend to have a higher percentage 
of body fat, which may lead to an increased distribution of 
lipophilic drugs. Women also have more active CYP3A4 
metabolism, which may lead to an increase in drug clearance. 
Men often have a higher glomerular filtration rates compared 
to women. Women renally clear certain drugs like digoxin, 
aminoglycosides, cephalosporins and fluoroquinolones slower 
compared to men.7 Compared to men, women can attain 
higher plasma concentrations of clozapine, which may be due 
to activity of cytochrome metabolizing enzymes and slower 
renal clearance rate in females.8 
 
In 2004, by the collaborative effort of many professional 
pharmacy organizations and the US Department of Health and 
Human Services Health Resources and Service Administration, 
a web-based search of each college or school of pharmacy was 
completed. The search reviewed each curriculum and course 
catalog to determine if courses were offered in women’s 
health or if women’s health is mentioned within other 
courses. The findings demonstrated that out of 89 US schools 
or colleges of pharmacy, 34 (approximately 40%) of those 
offered a women’s health course or classes that incorporate 
women’s health.9 
 
Because clinical differences exist between men and women,  
it is important that these differences are highlighted in the 
PharmD curriculum. The Accreditation Council for Pharmacy 
Education (ACPE) currently has no standard for the inclusion of 
gender and sex related differences in the didactic portion of 
the PharmD curriculum. ACPE does encourage advanced 
pharmacy practice experiences (APPEs) to include diverse 
populations related to gender.10  The American Association of 
Colleges of Pharmacy (AACP) collaborated with the Food and 
Drug Association’s (FDA) Office of Women’s Health to create a 
program that provides a curriculum of women’s health 
objectives that colleges may use as a guide.12  This program is 
not mandatory for pharmacy schools, but it is an available 
resource. Of the twelve Learning and Performance Outcomes, 
outcome three is listed as, “Sex and Gender Differences in 
Disease Presentation and Treatment.” The etiology, biological 
considerations and therapeutic management of gender- and 
sex-related differences are just a few of the suggested topics 
to cover. With a better understanding of these differences, 
student pharmacists may be better prepared to help and treat 
their patients and educate other members of the health care 
team. 
 
With the lack of standards by national pharmacy 
organizations, research into the breadth and depth of 
women’s health information provided to student pharmacists 
in required coursework, such as pharmacotherapeutics and 
pharmacokinetics, is important to the evolution of Doctor of 
Pharmacy (PharmD) curricula. Results from this survey may 
highlight gaps in the PharmD curriculum and may stimulate 
and encourage changes.  Specifically, faculty may use the 
results of this survey to help guide therapeutic areas for 
required courses and topics for their elective courses. In this 
exploratory study, it was hypothesized that gender- and sex-
related differences were discussed more commonly in elective 
courses compared to required coursework. It was also 
theorized that faculty may feel more pressured in the required 
curriculum to cover other areas of each clinical topic and may 
not include gender- and sex-differences due to time 
constraints.   
  
Methods 
A 23 question survey (available in Supplementary File 1) was 
created by the authors to determine how many clinical topics 
incorporated gender- and sex-related differences and to what 
extent this information was discussed in the classroom. The 
questions focused on the approximate amount of time in the 
classroom spent on clinical presentation, treatment, 
physiological differences, and 
pharmacokinetic/pharmacodynamics differences between 
males and females.  These main focus areas were selected 
because they were the subjects of recent research on this 
topic.2-8 In addition, they were considered relevant to PharmD 
curricula, as pharmacists may field questions about these 
areas when in practice. Respondents were also asked if this 
topic was taught in an elective or required course to address 
the author’s hypotheses. Additional questions were included 
related to awareness, perceived clinical importance, and 
perceived comfort in discussing these differences.  These 
areas were measured using 5-point ordered response items.  
For those who reported not teaching sex- or gender-related 
differences, a set of questions explored why these topics were 
not taught in their classes to identify if time was the reason. 
An open-ended response question was also included to obtain 
additional relevant faculty comments that may not have been 
captured by the survey questions.  
 
A survey link was emailed selectively to faculty teaching in 
pharmacotherapeutics and pharmacokinetics at the following 
colleges of pharmacy: Midwestern University Chicago College 
of Pharmacy, University of Illinois at Chicago, Roosevelt 
University, Rosalind Franklin University, and Chicago State 
University. These colleges of pharmacy were selected due to 
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the close proximity to each other in the Chicago area and were 
deemed representative of public and private institutions in 
exploring these hypotheses and questions in preparation for a 
comprehensive survey.  Because this was a regional sample of 
colleges, faculty email addresses were easily obtained from 
online resources and faculty listservs. The survey was not 
piloted, but remained open for four weeks with two 
reminders. 
 
The invitation email provided respondents with the objective 
of the study, the expected time it would take to complete, 
contact information to a primary investigator, and disclosure 
that no results would be linked to individual participants. Data 
were collected through REDCap (Research Electronic Data 
Capture, Vanderbilt University, Nashville Tennessee).  Text 
responses about clinical topic areas taught by respondents 
were categorized by the study investigators.  Quantitative 
items were analyzed using Stata/SE statistical software 
(College Station, TX: StataCorp LP; 2015). Chi-square tests 
were used to examine associations among the participants’ 
responses.  This study was reviewed by the Midwestern 
University Institutional Review Board and granted exempt 
status. 
  
Results 
The survey was emailed to 286 faculty members at five 
colleges/schools of pharmacy. A total of 56 faculty responded 
to the survey resulting in a 20% response rate. Overall, 30 
(55%) of respondents indicated they discussed gender- and/or 
sex-related differences in the subject areas in which they 
teach. Most of the respondents teach gender- and sex-related 
differences in one clinical topic (57%). The remaining 
respondents teach these differences in two (23%), three (6%) 
or four or more (14%) clinical topics. Using an open text box in 
the survey, respondents listed the types of clinical topics in 
which they discussed gender- and sex-related differences. 
Results were varied and are listed in Table 1.  It was noted that 
16% of these clinical topics are taught in elective courses. 
 
When faculty were asked about time spent, most respondents 
spent time discussing clinical presentation (Table 2). Time 
spent on clinical presentation, treatment options and 
pharmacodynamics/pharmacokinetics was mostly between    
1-10 minutes. None of the responding faculty spent more than 
20 minutes lecturing on gender- and sex-related differences. 
Faculty who spent time discussing physiological differences 
were also more likely to discuss pharmacokinetic and 
pharmacodynamic differences (p = 0.001). 
 
Respondents were also questioned about the clinical 
importance of gender- and sex-related differences on a scale 
of 1-5, with 1 being not at all important and 5 being very 
clinically important, (Figure 1). In addition, respondents were 
questioned regarding their level of comfort and awareness 
regarding gender- and sex-related differences. There was no 
association found between faculty who were aware of gender- 
and sex-related differences and who actually teach these 
difference in their subject area (p=0.384). There was also  no 
association found between how comfortable the respondent 
felt with the topic and the time spent teaching treatment 
option for gender- and sex-related differences (p=0.200). 
 
Utilizing skip-logic questions in the electronic survey, 
questions addressing barriers to teaching gender- and sex-
related differences were included if a respondent answered 
“no” to teaching these differences. A total of 26 respondents 
(46%) noted that they do not teach these differences. Of these 
respondents who reported that they do not teach gender- or 
sex-related differences at all, 94% (24 respondents) answered 
that gender- and sex-related differences were not relevant to 
the class or subject area and only 1 respondent answered that 
they do not have time to teach it. At the end of the survey, 
respondents were given the option for a free text box to 
express any additional thoughts or comments on gender- and 
sex-related differences in regards to importance and the 
PharmD curriculum. Table 3 lists all of the statements 
provided by respondents.  
  
Discussion 
This survey explores the incorporation of gender-and sex- 
related differences in the PharmD curriculum. Although over 
half of the surveyed faculty discuss gender and sex related 
differences, most only discuss the differences in one subject 
area. Surprisingly, the subject areas vary, which indicate that 
such differences exist across many disease states/conditions. 
The majority of respondents spent the most time discussing 
clinical presentation and treatment options for the specific 
topic. This may be because more information is known about 
these two areas. A survey was previously conducted 
addressing the incorporation of this content in medical 
education and it was found that the average time allocated to 
these topics in 176 medical schools in Canada and the United 
States was five hours, but the number of topics varied 
greatly.12 Compared to the results of this survey, incorporation 
in the PharmD curriculum is less compared to medical 
curriculum.  
 
This survey included questions to identify the barriers that 
exist to including this topic in lecture. It was hypothesized that 
faculty may feel pressured for time to cover the basics of each 
clinical topic and that differences between men and women 
may not be included due to time constraints. It was, however, 
surprising to find that most faculty who do not teach these 
topics felt that they were not relevant to the class or subject 
area.  
 
Only seven of the subject areas were included in an elective 
course, which is surprising because it was hypothesized that 
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gender- and sex-related differences would be discussed more 
commonly in elective courses, which typically allow for 
expanded discussion on disease states. With no current 
standard, faculty members independently choose to include 
gender- and sex-related differences in their lecture topics and 
the extent of the discussion, regardless of the course being an 
elective or required. If the difference between gender or sex is 
found to be clinically important to the lecturer, the 
information is provided to students regardless of the type of 
course. 
 
Most surveyed faculty found gender- and sex-related 
differences clinically important.  Faculty teaching in areas 
where gender- or sex-related differences are important should 
be reminded of valuable resources available, such as those 
from AACP on women’s health.12 As research regarding 
gender- and sex-differences continues to be published, faculty 
should consider evaluating the clinical implications of these 
findings and incorporate them into coursework. 
 
This project had several limitations. This project had a rather 
low response rate, so the ability of these results to represent 
all pharmacy faculty in the Chicago area is questionable.         
In addition, when the survey was initially sent to faculty 
members an error was made through the REDCap software, 
which collected unusable data, and a new email was sent 
including an explanation of the error and a new survey link. 
Faculty may have responded to the first survey link and not 
the correct link.   
 
Due to the low response rate, a new survey sent to additional 
pharmacy school faculty is warranted. A new survey will be 
administered nationally to increase generalizability and it will 
also address the incorporation of content related to treating 
lesbian, gay and transgender patients in the PharmD 
curriculum as this is also not addressed in ACPE standards.      
In addition, this survey will compare the time spent discussing 
gender- and sex-related differences to the total lecture time.  
 
Conclusion 
The results of this survey provide insight to the proportion of 
faculty who are teaching gender-and sex-related differences 
and the time allocated to these topics in the PharmD 
curriculum at five pharmacy schools. Lecture topics and 
inclusion barriers were explored, but a larger sample size is 
needed to capture the full breadth and depth of this topic, 
which will be addressed in a larger national survey.  Faculty 
members who are not teaching gender- and sex-related 
differences should be aware that some of their other 
colleagues are teaching these differences and that faculty 
members must choose to independently include this in their 
lectures. Overall, faculty members should be aware of gender- 
and sex-related medication differences and understand the 
importance of this incorporation into the PharmD curriculum.  
Disclosures:  None 
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Table 1. Clinical topics discussing gender- and sex-related differences 
 
Acute coronary syndromes 
Alcoholic liver disease 
   
Anticoagulation 
Childhood psychiatric Disorders  
Clinical decision-making  
Contraceptives  
Communications/counseling 
COPD and asthma  
   
Diabetes  
Dyslipidemia  
   
Fluid/electrolytes  
Inflammatory bowel disease/Irritable bowel syndrome  
Headache  
Lifestyle modifications*  
Nephrology  
Osteoporosis  
Preventive care*  
Sexually transmitted infections* 
Urinary incontinence Urinary tract infections 
   
*Discussed in an elective course 
 
 
Table 2. Approximate time spent discussing gender- and sex-related differences 
 
 1-5 min 6-10 min 11-15 min 16-20 min >20  min Do not teach 
Clinical Presentation 19 (7.6%) 7 (21.2%) 1 (3%) 1 (3%) 0 (0%) 5 (15%) 
Treatment Options 8 (24%) 8 (24%) 2 (6%) 6 (18%) 0 (0%) 9 (27%) 
PK/PD Differences 9 (27%) 4 (12%) 2 (6%) 2 (6%) 0 (0%) 16 (48.5%) 
 
 
 
 
Table 3. Faculty comments regarding gender- and sex-related differences and their incorporation into the PharmD curriculum. 
“Where there are physiological differences, where there are 
treatment recommendation differences and where there are 
PK/PD differences I teach them.” 
“Gender and sex related differences are important to consider in 
treating the patient…It is important to teach this 
individualization of medicine to better meet the needs of our 
patients.” 
“I think it is an interesting aspect that could apply heavily to 
some topic areas and very little to others.” 
 
“As more research is done in this area, it will need to be better 
integrated into the curriculum” 
“I do believe that gender and sex differences exist and are 
important. However, the extent of their effects on 
pharmacotherapy responses is not well known. Because the 
data is still very gray, it is not worth spending class time on the 
subject.” [From a respondent who indicated they do not teach 
gender- and sex-related differences] 
“I think there may also be social/cultural gender-based 
differences that could relate to the way patients therapies 
should be selected and the way should be counseled and 
communicated with.” 
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Figure 1: Faculty reported clinical importance of gender- and sex-related differences. 
 
 
Response options ranged from 1 “Not at all” to 5 “Very” 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
